Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

48.62USD
11 Feb 2016
Change (% chg)

$0.71 (+1.48%)
Prev Close
$47.91
Open
$48.69
Day's High
$48.71
Day's Low
$47.97
Volume
670,901
Avg. Vol
344,710
52-wk High
$60.34
52-wk Low
$42.42

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $101,812.60
Shares Outstanding(Mil.): 2,062.56
Dividend: 0.76
Yield (%): 1.59

Financials

  NVO.N Industry Sector
P/E (TTM): 23.44 31.28 37.85
EPS (TTM): 2.04 -- --
ROI: 73.94 14.74 14.09
ROE: 79.90 15.31 14.83
Search Stocks

European shares end lower on disappointing U.S data, weak earnings

* Italian lenders lead bank sector lower (Adds details, updates prices)

03 Feb 2016

EXECUTIVE VIEW -Novo optimistic about uptake of Tresiba in the U.S

COPENHAGEN, Feb 3 Novo Nordisk on Wednesday lowered its target for long-term profit growth after a slightly weaker than expected fourth quarter.

03 Feb 2016

UPDATE 2-Drugmaker Novo surprises with long-term profit target cut

* Novo cuts long-term EBIT growth target to 10 pct from 15 pct

03 Feb 2016

Novo Nordisk's Q4 EBIT misses slightly, lowers long-term growth target

COPENHAGEN, Feb 3 Novo Nordisk specified its 2016 guidance and lowered its target for long-term profit growth after a slightly weaker than expected fourth quarter.

03 Feb 2016

Novo's operating profits expected to jump, key drugs data ahead

COPENHAGEN, Jan 28 Denmark's Novo Nordisk is expected to announce a 44 pct rise in annual operating profits in its earnings report on Wednesday, as investors await crucial drug test results.

28 Jan 2016

BRIEF-Novo Nordisk launches Tresiba in the United States

* Long-acting Tresiba U-200 now available for adults living with diabetes

26 Jan 2016

Novo aims to be ahead of pharma pack with Iran investment

DAVOS/LONDON Danish drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan.

21 Jan 2016

Novo aims to be ahead of pharma pack with Iran investment

DAVOS/LONDON, Jan 21 Danish drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan.

21 Jan 2016

BRIEF-Novo Nordisk files for EU approval of haemophilia B treatment

* Says files for regulatory approval of long acting factor IX, nonacog beta pegol, in the EU for the treatment of haemophilia B

07 Jan 2016

Novo Nordisk files for EU approval of faster-acting diabetes drug

COPENHAGEN, Dec 4 Danish insulin maker Novo Nordisk has filed for regulatory approval of faster-acting insulin drug aspart in the EU to the European authorities, the company said on Friday.

04 Dec 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €67.27 --
Eli Lilly and Co (LLY.N) $71.42 -1.65

Earnings vs. Estimates

Search Stocks